|Home | About | Journals | Submit | Contact Us | Français|
Autosomal recessive interleukin (IL)-12 p40 (IL-12p40) deficiency is thought to be a rare genetic etiology of Mendelian susceptibility to mycobacterial disease (MSMD). We report the genetic, immunological and clinical features of 49 patients from 30 kindreds originating from 5 countries (India, Iran, Pakistan, Saudi Arabia and Tunisia). There are only 9 different mutant alleles of the IL12B gene: including 2 small insertions, 3 small deletions, 2 splice site mutations and 1 large deletion, all frameshift and leading to a premature stop codon, and 1 nonsense mutation. Four of these 9 variants are recurrent, affecting 25 of the 30 reported kindreds, due to founder effects in specific countries. All patients are homozygous and display complete IL-12p40 deficiency. As a result, the patients lack detectable IL-12p70 and IL-12p40 and have low levels of interferon gamma (IFN-γ). The clinical features are characterized by childhood onset of bacillus Calmette-Guérin (attenuated Mycobacterium bovis strain) (BCG) and Salmonella infections, with recurrences of salmonellosis (36.4%) more common than recurrences of mycobacterial disease (25%). BCG vaccination led to BCG disease in 40 of the 41 patients vaccinated (97.5%). Multiple mycobacterial infections were rare, observed in only 3 patients, whereas the association of salmonellosis and mycobacteriosis was observed in 9 patients. A few other infections were diagnosed, including chronic mucocutaneous candidiasis (CMC) (n=3), nocardiosis (n=2), and klebsiellosis (n=1). IL-12p40 deficiency has a high but incomplete clinical penetrance, with 33.3% of genetically affected relatives of index cases showing no symptoms. However, the prognosis is poor, with mortality rates of up to 28.6%. Overall, the clinical phenotype of IL-12p40 deficiency closely resembles that of interleukin 12 receptor β1 (IL12R-β1) deficiency. In conclusion, IL-12p40 deficiency is more common than initially thought and should be considered worldwide in patients with MSMD and other intra-macrophagic infectious diseases, salmonellosis in particular.
Mendelian susceptibility to mycobacterial disease (MSMD) is a rare clinical syndrome that was probably first described in 1951 (OMIM 209950) (2, 8, 9). MSMD is clinically characterized by susceptibility to poorly virulent mycobacteria, such as bacillus Calmette-Guérin (attenuated Mycobacterium bovis strain) (BCG) vaccines and environmental mycobacteria (EM), as well as non-typhoidal Salmonella (6, 19). The clinical features of MSMD patients are diverse, ranging from disseminated, overwhelming disease to localized, recurrent disease (3, 19). The patients are also vulnerable to more virulent, mycobacteria (M. tuberculosis) and typhoidal Salmonella (1, 12, 29, 33, 41). Other infections, with viruses or intra-macrophagic microorganisms, are rare (12, 40). Various modes of inheritance have been reported in multiplex kindreds, with autosomal recessive, autosomal dominant, and X-linked recessive patterns (3, 19, 40). Unsurprisingly, MSMD has been reported to be genetically heterogeneous (7, 20). Since 1996, MSMD-causing mutations have been found in 6 autosomal (IFNGR1, IFNGR2, STAT1, IL12RB1, IL12B and IRF8) and 2 X-linked (NEMO, CYBB) genes (5, 19, 24). Allelic heterogeneity further contributes to the definition of up to 15 genetic disorders, with complete and partial defects, dominant and recessive traits, and complete defects with and without protein production (5, 19, 24, 41, 47). With the possible exception of CYBB, MSMD-causing genes encode molecules involved in the IL-12-IFN-γ circuit, either in the IL-12-dependent induction of IFN-γ or cellular responses to IFN-γ (6, 10, 19). An account of the first patient with IL-12p40 deficiency was published in 1998 (4). Since then, there have been 4 other publications describing only 20 patients with IL-12p40 deficiency (14, 30, 33, 38). IL-12p40 deficiency is therefore thought to be a very rare genetic etiology of MSMD, estimated to account for less than 9% of cases (19).
In mice and humans, IL-12p70 is a heterodimeric cytokine composed of a 35-kDa light chain (p35) encoded by IL12A and a 40-kDa heavy chain (p40) encoded by IL12B (26,7 44). IL-12p70 is produced mostly by myeloid macrophages and dendritic cells (44) and plays a major role in inducing the production of IFN-γ by NK and T lymphocytes. IL-12p70 signals through a specific IL-12 heterodimeric receptor (IL-12R) consisting of IL-12Rβ1 and IL-12Rβ2 chains and is expressed principally on activated NK and T cells (34). The binding of IL-12 to IL-12R in NK and T cells leads to the janus kinase 2- and tyrosine kinase 2-dependent activation of signal transducer and activator of transcription factor (STAT) 4, leading to the translocation of this molecule to the nucleus, where it induces the transcription of target genes, including the IFN-γ and Furin genes, in particular (26, 32, 43). In mice, IL- 12R is also expressed by some myeloid cells, in which the IL-12 signaling pathway differs from that operating in lymphocytes, making use of nuclear factor kB instead of STAT (23). IL-12p40 is not specific for IL-12p70, as it can also associate with the IL-23p19 subunit to form IL-23, which is involved in the induction of IL-17-producing T cells (44). The heterodimeric IL-23 receptor also includes the IL-12Rβ1 chain. Individuals with IL12B mutations therefore have defects in both IL-12 and IL-23 immunity (26). Likewise, patients with IL-12Rβ1 deficiency do not respond to either IL-12 or IL-23 (12). Patients with IL-12p40 or IL-12Rβ1 deficiency suffer from MSMD because of impaired IL-12-dependent IFN-γ immunity; some suffer from Candida albicans infections because of impaired IL-23-dependent IL-17 immunity (11, 12, 35). We recently reviewed the clinical and genetic data from a large series of patients with IL-12Rβ1 deficiency (12). The aim of this study was to describe the genetic, immunological and clinical features of a large cohort of IL-12p40-deficient patients.
Patients and their families, including asymptomatic relatives, were recruited to this study through a large, worldwide network of collaborating clinicians and immunologists, from 1988 to 2012. These patients presented with a history of unusual infections, such as disseminated disease caused by weakly virulent mycobacteria and Salmonella, corresponding to the description of MSMD and other similar conditions. Healthy volunteers were also recruited. The study was conducted in accordance with the Helsinki Declaration, with informed consent obtained from each patient or the patient’s family, as well as the healthy volunteers, as required, and with the approval of the institutional review boards of the various institutions involved.
Venous blood samples were collected into heparinized tubes and were transported by express mail, at room temperature. We received a blood sample from a healthy blood donor together with each blood sample from a patient. Blood samples from healthy donors were collected at the same time and at the same institution as the patient’s blood sample and were transported with the patient’s blood sample. These samples are identified as “travel control” samples in the text. Blood was diluted 1/2 in RPMI 1640 medium (Invitrogen). We activated 1 ml of blood dilution per well of a 48-well plate as follows: with medium alone, with live BCG (Mycobacterium bovis BCG, Pasteur strain) at a multiplicity of infection of 20:1, with BCG and IFN-γ (5000 IU/ml, Imukin Boheringer Ingelheim) or with BCG and IL-12p70 (20 ng/ml, R&D Systems) (15). All cells were incubated at 37°C, under an atmosphere containing 5% CO2. Supernatants were collected after 48 hours and centrifuged at 1800 g for 10 minutes. The resulting supernatants were stored at −20°C until analysis.
IL-12p40, IL-12p70 and IFN-γ (in the 48-hours supernatant) were determined by ELISA. We used the capture antibodies, detection antibodies and standards supplied in the R&D Systems kits for IL-12p40 (Quantikine SP400) and IL-12p70 (Quantikine HS120) and in the Sanquin kit for IFN-γ (M9333), diluted in HPE dilution buffer. Milk was used for blocking and antibody binding was detected with streptavidin-conjugated horseradish peroxidase (M2032, Sanquin) and TMB microwell peroxidase substrate (50-76-00, KPL). The reaction was stopped by adding H2SO4 (1.8 M). Absorbance was determined with an MRX microplate reader (Thermolab Systems), at 490 nm for IL12p70 and at 450 nm for IL-12p40 and IFN-γ. The detection limits of the assays were 0.625 pg/ml for IL12p70, 15.6 pg/ml for IL-12p40 and 5 pg/ml for IFN-γ. Quantitative analysis was carried out with a non linear, four-parameter logistic (4PL) calibration model, with in-house software based on the Microsoft Excel application language developed for this purpose (a gift from Max Feinberg). Intermediate results for each cytokine are expressed in pg/ml/106 peripheral blood mononuclear cells (PBMC) (15).
Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-B cell lines) were cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen). Cells were incubated in 24-well plates at a density of 1×106 cells/ml with 2×10-7 M phorbol-12,13-dibutyrate (Sigma) for 18 h. EBV-B cell lines derived from a healthy individual and from a patient previously diagnosed with IL-12 deficiency (4, 33) were used as positive and negative controls, respectively. All cells were incubated at 37°C, under an atmosphere containing 5% CO2.
Human genomic DNA was isolated from the Ficoll gradient pellets obtained during PBMC purification and/or from the cell lines. The cells were lysed by incubation in extraction buffer (10 mM Tris, 0.1 M EDTA, 0.5% SDS, and 20 mg/ml proteinase K) overnight at 37°C. DNA was isolated by phenol/chloroform extraction, precipitated in isopropanol and ethanol and resuspended in autoclaved H2O. RNA was isolated from EBV-B cell lines with Trizol reagent (Invitrogen), according to the manufacturer’s instructions. RNA was reverse-transcribed with oligo-dT primers and Superscript II reverse transcriptase (Invitrogen). The first-strand cDNA was then stored at −20°C. PCR amplification was performed with the AmpliTaq DNA polymerase (Applied Biosystems) and the GeneAmp 9700 PCR system (Applied Biosystems). The primers and conditions used for PCR amplification of the coding exons, including the flanking intronic sequences or the IL12B cDNA are available on request. Amplified PCR products were checked by gel electrophoresis in a 1% agarose gel and purified by centrifugation through Sephadex G-50 Superfine resin (Amersham GE) on a MAHV-N45 filter-plate multiscreen (Millipore). PCR products were sequenced by dideoxynucleotide termination, with the BigDye Terminator kit v1.1 or v3.1 (Applied Biosystems) and the PCR primers. Sequencing products were purified by centrifugation through Sephadex G-50 Superfine resin and analyzed on an ABI Prism 3100 or 3130xl apparatus (Applied Biosystems). Sequence files and chromatograms were analyzed with GENALYS Software from the CNG, France (42).
The age of the 2 founder mutations, 315insA and 526del2, was estimated from a subset of 8 available unrelated 315insA patients from Saudi Arabia and 2 available unrelated 526del2 patients from Iran. Approximately 250,000 SNPs, from the Affymetrix GeneChip Human Mapping 250K, were genotyped. SNPs with 100% call rates were scanned for continuous stretches of homozygosity up- and downstream from the IL12B locus. Pairwise comparisons within each mutation group revealed the limits of the longest shared haplotype and the positions of subsequent recombination breakpoints. The likelihood-based ESTIAGE method (22) was used to estimate the age of the most recent common ancestor for each mutation from the observed shared haplotypes, together with recombination rates and haplotype frequencies obtained from the HapMap Project (21).
Infection-free status, survival and penetrance curves as a function of age were estimated by the Kaplan-Meier method. Penetrance curves for IL-12p40 deficiency were obtained from the data for 15 symptomatic relatives of index cases. The production of IL-12p40, IL12p70 and IFN-γ by whole blood cells was compared between controls and patients, in various stimulation conditions, by nonparametric Kruskal-Wallis rank sum tests. All calculations were carried out and curves plotted with R software (http://cran.r-project.org/).
We identified 30 kindreds, comprising a total of 49 IL12p40 deficient patients (30 index cases and 19 siblings), including 44 symptomatic and 5 asymptomatic subjects (Table 1, Figure 1). Detailed pedigrees were available for 29 families, 25 (86.2%) of which were consanguineous (mostly due to first-cousin marriages). Sequencing of the 6 IL12B coding exons and flanking intron regions in the 30 index cases from 5 different countries (India, Iran, Saudi Arabia, Pakistan, and Tunisia) revealed only 9 different mutant IL12B alleles (Figure 2), 5 of which had not previously been reported (Figure 3). The known mutations were 2 small deletions (526del2, 297del8) (16, 32), 1 insertion (315insA) (14, 30) and 1 large deletion (g.482+82_856-854del) (33). All 4 known mutations induced frameshifts, resulting in the generation of premature termination codons (526del2, 297del8, 35del10, 315insA) or the excision of 2 coding exons (g.482+82_856-854del). The 5 newly identified IL12B mutations comprised 1 deletion (35del10), 1 insertion (909insA), 1 nonsense mutation (W60X) and 2 splice-site mutations (697+2T>C and 697+5G>A). Each of these mutations was found in a single kindred. These previously unknown mutations had a major impact on the structure of the IL12B mRNA. The splice-site mutations (697+2T>C and 697+5G>A) led to the excision of exon 6 and an absence of full-length IL12 mRNA, as shown by RT-PCR (data not shown). The 909insA mutation resulted in the insertion of a premature stop codon at amino acid 60 (W60X). The most prevalent IL12B mutation was the previously reported 315insA mutation, which was detected only in patients from Saudi Arabia (n=24; 13 kindreds). The next most frequent mutation was the 297del8 mutation, which was identified exclusively in kindreds originating from Tunisia (n=8; 5 kindreds) (14, 33).
Figure 4 reports the clinical features of the 30 IL-12p40-deficient index cases. The first clinical symptoms occurred in childhood (mean age, 1.1 yr, SD 1.76 yr, range, 1 mo to 7.6 yr). BCG was, by far, the most frequent infectious agent, causing the first clinical manifestation of MSMD (n=27). Disseminated BCG disease (BCG-osis) was the most frequent presentation (19 of 27 cases), the other patients displaying regional BCG disease (BCG-its; 8 of 27). Salmonella (2.II.3), EM (6.II.5) and M. tuberculosis (18.II.1) were responsible for the first clinical manifestation in 1 index case each. Patients 2.II.3 and 6.II.5 were not vaccinated with BCG. Patient 18.II.1 was vaccinated with BCG at the age of 3 years, with no adverse reaction. Twenty of the 30 index cases (66.7%) presented BCG disease as the only MSMD-related infection during their lifetime. After BCG disease, 5 patients developed salmonellosis, 1 patient developed tuberculosis (20.II.3), and another patient developed both salmonellosis and EM disease (12.II.1). Salmonellosis and TB were the only relevant infections observed during the lifetimes of patients 2.II.3 and 18.II.1, respectively. Patient 6.II.5 developed salmonellosis soon after EM infection.
We assessed the IL-12 and IFN-γ responses of whole-blood cells from IL-12p40-deficient patients. We evaluated the production of IFN-γ, IL-12p40 and IL-12p70, after stimulation with BCG, BCG plus IL-12 and BCG plus IFNγ, as previously described (15-17). We tested blood from 22 patients from 19 different kindreds. All 9 mutant IL12B alleles were found among the 22 patients studied here. We compared the results obtained with cytokine determinations in the same stimulation conditions for whole blood from 44 healthy travel controls. The whole-blood cells of patients stimulated with live BCG alone or BCG plus exogenous recombinant IFN-γ produced no IL-12p40, whereas IL-12p40 was generated by the cells of healthy controls (p < 0.001 in both conditions), as shown by ELISA (Figure 5A). IL-12p70 production by cells from the patients was more severely impaired upon stimulation with BCG plus exogenous recombinant IFN-γ (p < 0.001) than upon stimulation with BCG alone (p = 0.12). Furthermore, following stimulation with BCG, the patients’ cells produced significantly less IFN-γ than the cells of healthy travel controls (p < 0.001). Simulation with a combination of IL-12 plus BCG increased IFN-γ levels in the whole blood of IL-12p40-deficient patients, albeit to levels that remained significantly lower than those in travel controls (p < 0.001) (Figure 5C). The cellular defect of IL-12p40 production in IL-12p40-deficient patients was further confirmed by the stimulation with PDBu of EBV-B cells lines derived from patients’ PBMCs (33). We have shown that IL-12p40-deficient patients have a lower than normal percentage of CD3+IL-17A+ cells ex vivo (11). However, their T-cell blasts responded to IL-23 stimulation by producing IL-17 (11). The leukocytes of the patients described here displayed complete IL-12p40 and IL-12p70 deficiencies and impaired, but not abolished IFN-γ production.
The distribution of the 9 different mutations observed in this cohort of IL-12p40-deficient patients did not overlap between different ethnic groups. A founder effect has been documented for g.482+82_856-854del, in 2 patients from Pakistan and India (33). This effect is thought to have occurred ~700 years ago (95% confidence interval: 216-2760 years) based on analyses with a method developed in our laboratory (22, 33). In the same study, the 315insA mutation, which is found only in patients from Saudi Arabia, was estimated to have first occurred ~1,100 years ago (528-2640 years) (33). This study added 10 new families, all from Saudi Arabia, to the original 4 families found to carry the 315insA mutation. Again, we estimated the date of the founder effect with a larger sample of 8 independent patients to ~ 1,100 years ago, with a smaller 95% confidence interval, extending from 650 to 1850 years (Figure 6). We also found that the 526del2 deletion segregating exclusively in 3 Iranian families resulted from a founder effect. We were able to date this founder event from the data for 2 independent individuals to ~ 600 years ago (175-2175 years). Finally, the 297del8 deletion is found only in Tunisian patients and is also the result of a founder effect that will be reported elsewhere (Barbouche et al., in preparation). In conclusion, we identified 4 variants specific to 4 regions that resulted from founder effects and segregated in 25 of the 30 kindreds reported here.
The 30 probands had a total of 104 siblings. Genotyping was carried out for 51 of the 104 siblings. Fifteen of the 51 genotyped siblings were homozygous for mutations in IL12B. Five of these 15 siblings were asymptomatic at last follow-up (1.II.1, 10.II.7, 13.II.5, 21.II.4), at the ages of 9 years (1.II.1), 2 years (10.II.7), 26 years (13.II.5), 7 years (21.II.4) and 3 months (29.II.2). All had the same cellular phenotype as their clinically affected IL-12p40-deficient siblings. Four of the asymptomatic siblings had not been vaccinated with BCG vaccinated and BCG vaccination status is unknown for the fifth (13.II.5). Nine of the 10 genetically affected and symptomatic siblings had been vaccinated with BCG vaccination and all developed BCG disease. The only genetically affected, symptomatic sibling not to have been vaccinated presented non-typhoidal salmonellosis at the age of 2 years as the first and only symptom of MSMD (2.II.3). Five genetically affected siblings had displayed BCG disease only, up to last follow-up (3.II.4, 4.II.2, 7.II.4, 10.II.4, 16.II.5) (Figure 7). One sibling developed disease caused by Nocardia asteroides (3.II.6). One patient presented multiple infections, with BCG disease, non typhoidal salmonellosis, and tuberculosis (4.II.4). One patient displayed BCG disease and candidiasis (6.II.4). Only 1 of the genetically affected siblings died (6.II.3); she presented BCG disease and salmonellosis at the ages of 3 and 18 months, respectively. She died at the age of 11 years from meningoencephalitis that had not been confirmed bacteriologically. The infectious phenotype of these 15 genetically affected symptomatic siblings was thus very similar to that of the 30 index cases (Figure 7). Four of the 53 non genotyped siblings displayed MSMD (2.II.1, 3.II.9, 16.II.1, 28.II.1). Three (2.II.1, 3.II.9 and 28.II.1) died of disseminated BCG disease, whereas the fourth (16.II.1) recovered from localized BCG infection. Eight of the remaining 53 non-genotyped siblings died from unknown causes. The 4 non genotyped MSMD patients were considered to be genetically affected in subsequent analyses relating to clinical descriptions, giving a total of 44 symptomatic patients (30 index cases, 10 genotyped siblings, and 4 non genotyped siblings). However, only genotyped subjects were used for penetrance estimation, as we do not know how many of the non genotyped siblings were genetically affected but asymptomatic.
Mycobacterial diseases were the most frequent infections, diagnosed in 42 of the 44 symptomatic patients (95.45%). Infections caused by BCG vaccine accounted for 95.23% of all mycobacterial diseases. Thirty-seven of the genotyped patients had been vaccinated with BCG and 36 (97.3%) developed BCG disease (localized, n = 13; disseminated, n = 23). Only 1 genotyped patient was vaccinated with BCG but did not develop an adverse reaction (18.II.1), and this patient was vaccinated later than the others, at the age of 3 years. Adverse reactions to BCG vaccination were significantly more frequent (p = 0.002) in patients with IL-12p40 deficiency (97.3%) than in patients with IL-12Rβ1 deficiency (76.4%, 84 of the 110 vaccinated patients). Far fewer patients (2 of the 44) developed EM disease, due to Mycobacterium chelonae in both cases. One of these patients had an EM infection followed by salmonellosis (6.II.5); the other developed BCG, EM and Salmonella infections, as well as a surgical site infection due to Klebsiella spp. (12.II.5). Disseminated TB was found in 2 patients. One of these patients developed TB in combination with BCG disease (21.II.3). The second (18.II.1) was not vaccinated with BCG until the age of 3 years and developed disseminated tuberculosis at the age of 5 years. Patient 18.II.1 also presented Candida infection. Recurrence was defined as a subsequent episode of disease with the same microorganism after a period free from clinical symptoms and treatment. Eleven cases (BCG, n= 10; tuberculosis, n= 1) presented recurrent mycobacterial disease. Eight of the 10 deaths among the 44 symptomatic patients were due to mycobacterial disease. BCG disease was the only type of mycobacterial infection resulting in death.
Salmonellosis occurred in 11 patients (25%). It was the only infectious disease in 2 patients (2.II.3, 19.II.4), neither of whom had been vaccinated with BCG. The other 9 patients with salmonellosis also had BCG disease (n = 6), EM disease (n = 1), EM and BCG disease (n = 1) or tuberculosis and BCG disease (n= 1). Several serotypes of non typhoidal Salmonella were identified in our patients: S. enteriditis, n = 3; Salmonella gallinarum, n = 1; S. group B, n = 1; S. group C, n = 1; S. group D, n = 2. Salmonella serotype was not determined in 3 patients (1.II.1, 2.II.3, 13.II.1). Disseminated disease was the most common presentation (n= 5), followed by adenitis (n = 4) and gastroenteritis (n = 1). Recurrent salmonellosis was found in 36.4% of the cases and was more frequent than BCG disease recurrence (25%).
Nocardia, an intra-macrophagic pathogen closely phylogenetically related to Mycobacterium, caused disease in 2 patients (Nocardia brasiliensis, n = 1; Nocardia asteroides, n = 1). Both these patients also displayed BCG disease. Klebsiella pneumoniae, a Gram-negative enterobacterium closely related to Salmonella, caused disease in 1 patient (12.II.5), who also had several other infections (BCG, Salmonella and EM). Three patients displayed Candida albicans infections (6.II.4, oral thrush; 16.II.2, disseminated; and 18.II.1, oral thrush). The incidence of Candida infections was significantly lower (p = 0.006) in IL-12p40-deficient patients (6.7%) than in IL-12Rβ1-deficient patients (24%). Mean age did not differ significantly between the IL-12p40-deficient patients (mean: 9.7 years, SD: 7.74 yr, range: 3 mo- 34 yr) and the IL-12Rβ1-deficient patients (mean: 11.2 yrs, SD: 9.7 yr, range: 6 mo-46.4 yr), and therefore cannot account for this observation. We and others have reported the presence of autoantibodies against IL-17A, IL-17F, and IL-22 in patients suffering from chronic mucocutaneous candidiasis (CMC) and autoimmune polyendocrine syndrome type I (27, 36). We also identified autosomal dominant IL-17F deficiency, autosomal recessive IL-17RA deficiency and dominant gain-of-function STAT1 mutations as responsible for disease in patients with CMC (28, 35, 45). The impaired development of IL-17-producing T cells in at least some IL-12p40- and IL-12Rβ1-deficient patients (11) probably accounts for their susceptibility to candidiasis (37). Finally, patient 7.II.2 presented fulminant VZV infection, which may or may not result from IL-12 deficiency (39).
Consistent information concerning the onset of clinical symptoms was available for 42 of the 44 symptomatic patients: 30 index cases and 12 siblings. First infection occurred early in childhood, at a mean age of 1 year (range, 1 m to 7.6 yr; SD 1.59 yr) (Figure 8). BCG was the most frequent causal agent (n = 40) and disseminated disease occurred as the first clinical manifestation of MSMD in 25 patients. BCG disease occurred at children as young as 1 month, with a mean age at onset of 9 months (range, 1 mo- 7.6 yr, SD 1.39 yr). In 35 cases (83.3%), BCG disease occurred within 1 year of vaccination. The mean time from BCG vaccination to disease was 6.37 months (range, 1 mo- 4.16 yr, SD 7.95 mo). The onset of salmonellosis (n = 11) occurred over a larger range of ages, extending from 3 months to 33 years (mean 5.39 yr, SD 9.78 yr). EM infection was found in 2 patients, at the ages of 3 and 4 years. Mean age at the onset of tuberculosis was 2.8 years (range, 6 mo to 5 yr, SD 2.25 yr). We can conclude that BCG disease was not only the most frequent infection in IL-12p40-deficient patients, but also the infection with the earliest age at onset.
The mortality rate among symptomatic patients was 31.8% (14 of the 44 symptomatic patients) (Table 1). This is close to the rate of 38% reported in a series of 13 IL-12p40-deficient patients (33). Global mortality for all patients, including the 5 asymptomatic patients, was 28.6%. The mean age at death was 7.1 years for the 14 IL-12p40-deficient patients who died (range, 1.25-34 yr, SD 8.33 yr; Figure 9). Most of the deceased patients died from disseminated BCG infection (n = 10). One patient survived multiple relapses of disseminated BCG disease (9.II.1) but succumbed to disseminated salmonellosis at the age of 34 years. Fulminant VZV infection caused the death of a second patient (7.II.2) who survived at least 5 relapses of BCG disease. Patient 6.II.5 was not vaccinated with BCG and died from disseminated EM infection (M. chelonae). For the remaining patient (6.II.3), the pathogen causing the central nervous system infection that resulted in death could not be identified. Only 12 of the 44 symptomatic patients received human recombinant IFN-γ together with specific antibiotic treatment during infection; 5 of these patients have since died. One patient developed biliary cirrhosis during human recombinant IFN-γ treatment and underwent liver transplantation (38). More rarely, patients underwent surgical resection of the affected areas (lymph nodes, n = 2; bone, n = 1). We are currently collecting data to evaluate the impact of current treatment options and preventive management on outcome for IL-12p40-deficient patients.
Five of the 15 genetically affected siblings did not present MSMD-related or other unusual infections at last follow-up (follow-up range: 3 months to 26 yr; mean 8.85 yr, SD 10.23 yr). For the estimation of clinical penetrance, we excluded 1 symptomatic patient about whom we had no information concerning age at first infection. The overall clinical penetrance of infections (Figure 10) increased rapidly from 0.45 (95% confidence interval [CI], 0.1-0.65) at the age of 7 months, to 0.71 (95% confidence interval [CI], 0.29-0.88) by the age of 48 months. All 3 siblings over the age of 5 years are asymptomatic. Ten of 11 genotyped relatives who had been vaccinated with BCG presented BCG infection, of the disseminated form in 5 of these individuals. Two of these patients also presented salmonellosis or salmonellosis and tuberculosis. One patient, who had not been vaccinated with BCG, presented salmonellosis only.
IL-12p40 deficiency is commonly thought to be a very rare immunodeficiency. We show here that it is more frequent than was previously thought. The last IL12B mutation to be identified and reported was published in 2005 (4, 14, 30, 33, 38). We have since identified 5 other mutations resulting in IL-12p40 deficiency. All patients with a given mutation have the same ethnic origin (Saudi Arabia, Tunisia, India/Pakistan, Iran), providing evidence for underlying founder effects. These founder effects have been studied for 3 of the 4 recurrent mutations (482+92_856-854del, 315insA, 526del2). The possible date of origin of the mutations varies from 600 years ago in Iran to 875 years ago in Saudi Arabia. Despite genotypic heterogeneity, with 9 mutant alleles, the immunological phenotype remains homogeneous, with a complete deficiency of IL-12p40 and IL-12p70. No patients with IL-12p40 deficiency have yet been diagnosed in countries with a low prevalence of consanguinity, even in countries with national BCG vaccination programs, such as France. This suggests that mutant IL12B alleles are very rare and that heterozygosity for these alleles may be subject to negative selection at the population level. In any case, IL-12p40 deficiency remains the most common inborn error of cytokines, leading to primary immunodeficiency, as mutations in IL-17F have been found in only 4 patients (35). IL-12p40 deficiency remains the only known AR cytokine defect, the other known defect being AD (35).
Like the genotype, the clinical phenotype is more heterogeneous than the cellular phenotype. Clinical signs begin early in childhood, at a mean age of 1 year, as reported for IL-12Rβ1-deficient patients (12) and patients with the complete form of IFN-γR deficiency (13), but earlier than suggested by recently published data for partial recessive IFN-γR1 deficiency (mean, 11.25 years) (41). With an increase in the number of identified IL-12-p40-deficient patients from 13 to 49 cases, we observed a decrease in overall mortality rate from 38% (33) to 28.6%, with a mean age at death of 7.1 years. These data contrast with those for IL-12Rβ1-deficient patients (12), for whom an increase in mortality rate (from 15% to 32%) was observed together with increases in the number of cases (12, 18). Mortality rates and clinical penetrance are similar for these 2 diseases, with clinical penetrance reaching 50% before the age of 12 months for both IL-12p40 and IL-12Rβ1 deficiencies (12). Overall clinical penetrance is about 80% for both diseases (12). BCG infection was the most frequent disease and the main cause of death in IL-12p40-deficient patients. Only 1 of the patients vaccinated with BCG (18.II.1) did not present BCG disease, and this patient was not vaccinated until the age of 3 years. Salmonellosis was the sole clinical manifestation in 2 patients not vaccinated with BCG vaccine and another 9 patients developed salmonellosis in combination with other MSMD-related pathogens. This observation, together with the high incidence of salmonellosis as the only infection in IL-12Rβ1-deficient patients (21 of 57 cases of salmonellosis) (12), highlights the importance of IL-12p40 and IL-12Rβ1 for protective immunity against Salmonella, via IL-12 and/or IL-23. Non typhoidal, extraintestinal salmonellosis should lead physicians to check for IL-12p40 and IL-12Rβ1 deficiencies.
Other infectious agents related to the classical MSMD pathogens were found in our cohort of patients. For at least 3 of these pathogens, IL-12 is known to be required for the generation of an appropriate immune response. As expected, due to the impaired IL-17 immunity previously reported in patients with IL-12p40 deficiency (12), our patients were susceptible to mucocutaneous Candida infections. K. pneumoniae was found in patients with IL12-p40 and IL-12Rβ1 deficiencies. Both IL-17 and IL-23 have been shown to be important for the immune responses to Klebsiella and Salmonella (25, 29). This may account for the higher frequency of Salmonella and Klebsiella infections in patients with IL-12p40 or IL-12Rβ1 deficiencies than in patients with IFN-γR deficiency (12, 29). Nocardia asteroides, an intra-macrophagic pathogen, was previously described in 1 IL-12p40-deficient patient (33). We report here an additional patient presenting Nocardia brasiliensis infection. In both these cases, Nocardia infection was associated with BCG disease. Infection with a third Nocardia species (N. nova) was the only clinical sign in 1 IL-12Rβ1-deficient patient (12). Other intracellular pathogen infections found in IL-12Rβ1-deficient patients, such as paracoccidioidomycosis (31), coccidioidomycosis (46), histoplasmosis, toxoplasmosis and leishmaniasis (12), have yet to be diagnosed in patients with IL-12p40 deficiency. However, IL-12Rβ1 deficiency has been diagnosed in 30 countries, whereas IL-12p40-deficient patients have been diagnosed in only 5 countries to date. Overall, IL-12p40 deficiency is not as rare as previously thought, and its outcome is more favorable than suggested by the description of a smaller group of patients. We can also conclude that IL-12p40 deficiency is clinically indistinguishable from IL-12Rβ1 deficiency; the modest differences documented probably reflect the differences in size and ethnic backgrounds of the 2 population samples. This description of IL-12p40 deficiency in a large series of patients should help to increase awareness, improving the accuracy of diagnosis and patient care.
We would particularly like to thank the patients, their families and their physicians, whose trust, support and cooperation were essential for collection of the data used in this study. We thank all members of the laboratory for helpful discussions. We thank M. Courat, C. Bidalled, M. N’Guyen, T. Leclerc, Y. Nemirovskaya, T. Nivare and T. Kochetkov for secretarial and technical assistance. The Laboratory of Human Genetics of Infectious Diseases is supported by institutional grants from INSERM and The Rockefeller University, and grants from the Agence Nationale de la Recherche (ANR), European Union HOMITB (E08153KK) and NEOTIM (018736) grants, the St. Giles Foundation, the Thrasher Research Fund, the Jeffrey Modell Foundation, Talecris Biotherapeutics, National Institutes of Health (1R01AI089970-01), and the Rockefeller University Center for Clinical and Translational Science grant number 8UL1TR000043 from the National Center for Research Resources and the National Center for Advancing Sciences (NCATS). A. Samarina was supported by an Institut Pasteur fellowship. J.L. Casanova was an International Scholar of the Howard Hughes Medical Institute from 2005 to 2008.
The authors have no conflicting financial interests to report.
The authors declare no conflicts of interest.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.